Article citationsMore>>
Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefèbvre, P.J., Murray, G.D., Standl, E., Wilcox, R.G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R.J., Korányi, L., Laakso, M., Mokán, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W., Schernthaner, G., Schmitz, O., Skrha, J., Smith, U. and Taton, J., (2005) PROactive investigators. Secondary prevention of macrovascular events in patients with type 2
has been cited by the following article:
-
TITLE:
Pioglitazone does not modify ANP levels of type 2 diabetic patients
AUTHORS:
Stefano Benedini, Paolo Villa, Livio Luzi, Maurizio Bevilacqua
KEYWORDS:
Atrial Natriuretic Peptide; Pioglitazone; Insulin Resistance; Blood Glucose
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.2 No.4,
October
30,
2012
ABSTRACT: Background: The atrial natriuretic peptide (ANP) regulates fluid volume redistribution between heart and the pulmonary vessels. In diabetic patients the physiological action of ANP appears to be seriously altered. Methods: 12 subjects (gender 6M/6F, age 47 ± 2 years, BMI 29.1 ± 0.1 kg/m2), with type 2 diabetes and under stable conditions, were studied after one month of pioglitazione treatment (30 mg/die) by means of isotonic blood volume expansion. Results: After one month of pioglitazone treatment the meta- bolic profile of the subjects improved (decrease dia- stolic blood pressure: p = 0.05, total cholesterol: p = 0.01, triglycerides: p = 0.03 and blood glucose: p = 0.01) as the expansion of their plasma volume was found associated with the decrease of hematocrit (p
Related Articles:
-
Casimir Komenan
-
Mohammad Reza Farahani, Wei Gao
-
Mirwais Rashid
-
Mudassar Iqbal, Anima Langer, Afroz Alam
-
Arezoo Omati, Kambiz Davari, Borhan Shokrolahi